论文部分内容阅读
目的:采用Meta分析方法评价参芪扶正注射液治疗脑梗死的临床疗效及安全性.方法:计算机检索中国期刊全文数据库(CNKI)、中文科技期刊全文数据库(VIP)、万方数据库、中国生物医学文献数据库(SinoMed)、PubMed、Cochrane Library、Embase数据库中关于参芪扶正注射液治疗脑梗死的随机对照试验,采用Cochrane风险评价表评价其方法学质量,提取资料并通过RevMan 5.3软件进行数据分析.结果:共纳入7篇文献,累计535例受试者.Meta分析结果显示与未使用参芪扶正注射液的对照组比较,使用参芪扶正注射液的治疗组在治疗脑梗死方面的临床总有效率较高(RR=1.31,95％CI:1.19 ～1.43,P＜0.000 01),此外,治疗组还可以更好地降低脑梗死患者纤维蛋白原指数(MD=-1.36,95％ CI:-1.47～-1.25,P＜0.000 01)、血浆黏度(MD=-0.31,95％ CI:-0.54 ～-0.07,P=0.01)、改善神经功能缺损程度等.结论:当前证据表明,在临床治疗脑梗死过程中,加用参芪扶正注射液可以提高临床总有效率、改善神经功能缺损程度、改善血液流变学指标,但其安全性仍需进一步探讨.“,”Objective:To systematically evaluate the clinical efficacy and safety of Shenqi Fuzheng injection in treatment of cerebral infarction.Methods:Randomized controlled trials (RCTs) regarding Shenqi Fuzheng injection in the treatment of cerebral infarction in CNKI,VIP,Wanfang Database,PubMed,Cochrane Library,Embase by September 2016.Quality of included RCTs was evaluated by The Cochrane Risk of Bias Assessment Tool,and then the required information was extracted and Meta-analyzed by RevMan 5.3 software.Results:A total of 7 RCTs with 535 participants were included.In the Meta analysis,Shenqi Fuzheng injection could achieve a better effect than the group without Shenqi Fuzheng injection in respect of total effective rate (RR =1.31,95％ CI:1.19-1.43,P ＜ 0.000 01).In addition,it could decrease the index of fibrinogen (MD =-1.36,95％ CI:-1.47--1.25,P ＜ 0.000 01),the plasma viscosity (MD =-0.31,95％ CI:-0.54--0.07,P =0.01),and achieve a better effect in the degree of neurological impairment.Conclusion:Shenqi Fuzheng injection is more effective in improving the total effective rate,the hemorrheological indexes and the neurologic impairment.However,the evidence of Shenqi Fuzheng injection for treating cerebral infarction requires large-scale and double-blind RCTs to substantiate these findings.